Cancer nanotherapeutics in clinical trials. (Q38431604)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25895874%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

review article

1 reference

title

Cancer nanotherapeutics in clinical trials (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25895874%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25895874%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25895874%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

James C Kaczmarek

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25895874%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Robert Langer

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25895874%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

publication date

1 January 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25895874%20AND%20SRC:MED&resulttype=core&format=json

Cancer Treatment and Research

6 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25895874%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

volume

166

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25895874%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

page(s)

293-322

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25895874%20AND%20SRC:MED&resulttype=core&format=json

The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect

6 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Antibody therapy of cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Combining immunotherapy and targeted therapies in cancer treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Clinical development success rates for investigational drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Risks in new drug development: approval success rates for investigational drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

The price of innovation: new estimates of drug development costs

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Gene silencing in mammals by small interfering RNAs

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Mechanisms of cancer drug resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Knocking down barriers: advances in siRNA delivery

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Delivery materials for siRNA therapeutics

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Nanovector delivery of siRNA for cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Magnetic nanoparticles: synthesis, functionalization, and applications in bioimaging and magnetic energy storage

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Iron oxide nanoparticles for targeted cancer imaging and diagnostics.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Near-infrared fluorescent nanoparticles as combined MR/optical imaging probes

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Enhancement of anti-tumor activity of 1-beta-D-arabinofuranosylcytosine by encapsulation in liposomes

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Liposomal drug delivery systems: from concept to clinical applications

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Doxil®--the first FDA-approved nano-drug: lessons learned

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Large unilamellar liposomes with low uptake into the reticuloendothelial system

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome).

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Treatment of HER2-positive breast cancer: current status and future perspectives.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

EGFR and cancer prognosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

EphA2 expression is associated with aggressive features in ovarian carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Rational design of cationic lipids for siRNA delivery

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

A combinatorial library of lipid-like materials for delivery of RNAi therapeutics

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Lipid-like materials for low-dose, in vivo gene silencing

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

In vitro-in vivo translation of lipid nanoparticles for hepatocellular siRNA delivery

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

RNAi-mediated gene silencing in non-human primates.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Targeting polo-like kinase 1 for cancer therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Knockdown of β-catenin with dicer-substrate siRNAs reduces liver tumor burden in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Design and development of IT-101, a cyclodextrin-containing polymer conjugate of camptothecin

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

New class of polymers for the delivery of macromolecular therapeutics

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Impact of tumor-specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Protein nanoparticles as drug carriers in clinical medicine

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Phase I study of weekly nab-paclitaxel + weekly cetuximab + intensity-modulated radiation therapy (IMRT) in patients with stage III-IVB head and neck squamous cell carcinoma (HNSCC).

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

The rapamycin-sensitive signal transduction pathway as a target for cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Polymer conjugates as anticancer nanomedicines

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

HPMA copolymers: origins, early developments, present, and future

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Do HPMA copolymer conjugates have a future as clinically useful nanomedicines? A critical overview of current status and future opportunities.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Synthesis of a macromolecular camptothecin conjugate with dual phase drug release

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Pharmacokinetics and antitumor efficacy of XMT-1001, a novel, polymeric topoisomerase I inhibitor, in mice bearing HT-29 human colon carcinoma xenografts

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Physical and chemical properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Iron oxide-enhanced MR lymphography: the evaluation of cervical lymph node metastases in head and neck cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Prostate cancer: detection of lymph node metastases outside the routine surgical area with ferumoxtran-10-enhanced MR imaging

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

The safety and efficacy of ferumoxytol therapy in anemic chronic kidney disease patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Ultrasmall superparamagnetic iron oxides (USPIOs): a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic fibrosis (NSF)?

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Optimization of dye-doped silica nanoparticles prepared using a reverse microemulsion method

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Enhanced leukemia cell detection using a novel magnetic needle and nanoparticles

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

Nanoscale radiotherapy with hafnium oxide nanoparticles

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-16555-4_13

10.1007/978-3-319-16555-4_13

31 March 2020

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25895874%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25895874%20AND%20SRC:MED&resulttype=core&format=json